Renal Disease in Monoclonal Gammopathies
- PMID: 29763127
- Bookshelf ID: NBK499952
Renal Disease in Monoclonal Gammopathies
Excerpt
Kidney impairment is a worldwide public health issue with a rising incidence and prevalence, and it imparts a significant burden on the healthcare system with relatively poor outcomes. Multiple myeloma is a plasma cell disorder characterized by the clonal proliferation of malignant plasma cells, producing monoclonal proteins and causing end-organ damage. It mainly affects older people and accounts for around 10% of all hematologic malignancies. Patients with multiple myeloma and other monoclonal gammopathies often have kidney dysfunction due to a wide range of associated pathologies.
The involvement of the kidney in multiple myeloma and other plasma cell dyscrasias is widespread. At the time of presentation, up to 50% of the patients have kidney involvement, which is associated with higher mortality. Renal failure is the second most common cause of mortality in patients with multiple myeloma, second only to infections.
A patient can fall anywhere on the spectrum of kidney impairment, ranging from mild and reversible acute kidney injury (AKI) to severe impairment needing hemodialysis. Some patients with multiple myeloma have a slow progression of kidney dysfunction over 6 months or more. These patients tend to have chronic kidney disease (CKD) and can potentially need hemodialysis.
Monoclonal gammopathy-related renal disease can be classified into immunoglobulin-mediated or non-immunoglobulin–mediated, but considerable overlap and interaction between these categories can exist. In addition, the location of renal injury can be glomerular, tubulointerstitial, vascular, or a combination. Autoimmune involvement and complement activation are also common. The resulting pathophysiology includes AKI, CKD, proteinuria, hematuria, renal crystallopathy, and Fanconi syndrome.
Cast nephropathy is by far the most common renal disease associated with multiple myeloma, found in 40% to 60% of renal biopsies in patients with multiple myeloma and kidney disease. The term "myeloma kidney" usually refers to this entity. However, cast nephropathy can also be found in other disorders causing renal protein overload, and the presence of cast nephropathy does not necessarily exclude other types of kidney disease secondary to monoclonal gammopathy.
Other types of kidney disease with monoclonal gammopathies are amyloidosis, monoclonal immunoglobulin deposition diseases, fibrillary glomerulonephritis, immunotactoid glomerulopathy, type I cryoglobulinemia, proliferative glomerulonephritis with monoclonal IgG deposits, C3 glomerulopathy with monoclonal gammopathy, and renal crystallopathies.
Copyright © 2024, StatPearls Publishing LLC.
Conflict of interest statement
Sections
- Continuing Education Activity
- Introduction
- Etiology
- Epidemiology
- Pathophysiology
- Histopathology
- History and Physical
- Evaluation
- Treatment / Management
- Differential Diagnosis
- Prognosis
- Complications
- Deterrence and Patient Education
- Pearls and Other Issues
- Enhancing Healthcare Team Outcomes
- Review Questions
- References
Similar articles
-
The Scope of Kidney Affection in Monoclonal Gammopathies at All Levels of Clinical Significance.Turk J Haematol. 2017 Dec 1;34(4):282-288. doi: 10.4274/tjh.2017.0197. Epub 2017 Aug 23. Turk J Haematol. 2017. PMID: 28832010 Free PMC article. Review.
-
[Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].Presse Med. 2012 Mar;41(3 Pt 1):276-89. doi: 10.1016/j.lpm.2011.11.008. Epub 2012 Jan 13. Presse Med. 2012. PMID: 22244725 Review. French.
-
Spectrum of manifestations of monoclonal gammopathy-associated renal lesions.Curr Opin Nephrol Hypertens. 2016 Mar;25(2):127-37. doi: 10.1097/MNH.0000000000000201. Curr Opin Nephrol Hypertens. 2016. PMID: 26735145 Review.
-
Monoclonal Immunoglobulin Deposition Disease and Related Diseases.J Nippon Med Sch. 2019;86(1):2-9. doi: 10.1272/jnms.JNMS.2019_86-1. J Nippon Med Sch. 2019. PMID: 30918151 Review.
-
Combined renal proximal tubulopathy and crystal storing histiocytosis in a patient with κ light chain multiple myeloma.Pathologica. 2021 Aug;113(4):285-293. doi: 10.32074/1591-951X-154. Pathologica. 2021. PMID: 34463673 Free PMC article.
References
-
- Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005 Jun;67(6):2089-100. - PubMed
-
- Gödecke V, Schmidt JJ, Bräsen JH, Koenecke C, Haller H. [Diagnosis and treatment of kidney involvement in plasma cell diseases : Renal involvement in multiple myeloma and monoclonal gammopathies]. Internist (Berl) 2019 Jan;60(1):10-22. - PubMed
-
- Boudhabhay I, Titah C, Talbot A, Harel S, Verine J, Touchard G, Kaaki S, Gabison E, Vasseur V, Mauget-Faÿsse M, Sené T. Multiple myeloma with crystal-storing histiocytosis, crystalline podocytopathy, and light chain proximal tubulopathy, revealed by retinal abnormalities: A case report. Medicine (Baltimore) 2018 Dec;97(52):e13638. - PMC - PubMed
-
- Korbet SM, Schwartz MM. Multiple myeloma. J Am Soc Nephrol. 2006 Sep;17(9):2533-45. - PubMed
-
- Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol. 2000 Sep;65(3):175-81. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous